Compound profile · Recovery research

ELEVATE

Tissue research Janoshik verified
StatusResearch use only
BPC-157 - 10 mg
BPC-157 - 10 mg
Dhs. 349.00
Shop now
01

A fragment built to protect

BPC-157 is a synthetic stretch of a larger protective protein found in the digestive tract. It has been examined across tendon, muscle, gut and vascular injury - a broad, well-replicated signal in animal models.

01
Angiogenic signalling
Linked in vitro to new blood-vessel formation via the VEGFR2 / nitric-oxide pathway.
02
Fibroblast behaviour
Animal data suggest faster migration and collagen organisation at injury sites.
03
Gastric stability
Resists breakdown in stomach acid rare for a peptide, and the basis for oral research formats.
Primary structure
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
C62 H98 N16 O22 · 1419.6 g/mol
Calculate your reconstitution dosage →
03

At a glance

15
Amino acids
~8–30
Min half-life (rat)
137525-51-0
CAS
04

A short chain, a broad reach.

BPC-157 is notable for stability - it resists breakdown in gastric acid, which is unusual for a peptide and underlies interest in oral research formats.

Its proposed mechanism is pleiotropic rather than single-target: nitric-oxide modulation, growth-factor receptor interaction, and influence on pathways tied to angiogenesis and cell migration. That breadth is part of why effects appear across many tissue models and part of why mechanism is still debated.

05

Reading the evidence honestly

Not every claim made about BPC-157 carries equal weight. Apex Academy separates findings into three tiers based on how well-replicated and how directly applicable to humans the underlying research actually is.

Tier 01 - Strongest support
Well-replicated in animal models
  • Accelerated tendon-to-bone repair in rodent models
  • Gastroprotective effects across multiple animal studies
  • In vitro angiogenesis and fibroblast migration
Tier 02 - Moderate / preclinical
Promising, less established
  • Neuroprotective signals in animal injury models
  • Modulation of gut–brain and inflammatory pathways
  • Anecdotal human recovery reports (unverified)
Tier 03 - Emerging / unverified
Speculative, not established
  • Systemic anti-ageing claims
  • Human dose-response and long-term safety data
  • Oral bioavailability comparisons versus injection in humans
06

How it works

Research has examined several distinct signalling pathways, summarised below.

01
Angiogenesis

Promotes endothelial tube formation via VEGFR2 in cell models.

02
Nitric-oxide axis

Interacts with the NO system implicated in vascular and gut protection.

03
Growth-factor crosstalk

Associated with EGR-1 and growth-factor signalling at wound sites.

04
Gut integrity

Repeatedly protective against induced GI lesions in rodent studies.

07

How it moves through the system

AdministrationPeakHalf-lifeCleared
Peak 50% Cleared
15–30 min
Onset to peak
Minutes (rapid)
Half-life
2 - 4 h
Largely cleared
Curve shape is illustrative; figures reflect pharmacokinetics reported in research — rapid local metabolism, figures from animal IV/IM data.
08

Used in the lab, not the clinic

Reference figures describe how this compound is handled and dosed in research. These are not instructions for human use.

Format & handling
Research formatLyophilised
ReconstitutionBacteriostatic water
Cold-chainRecommended
In the literature
Doses in literatureµg/kg (animal)
Storage−20 °C lyophilised
Stability (reconstituted)~weeks, refrigerated
09

Reconstitution calculator

How much diluent to mix into the vial, and the concentration that results. The suggested volume reaches a clean working stock; the calculator does the arithmetic from figures you enter. These describe solution preparation for research handling — not instructions for use in humans or animals.

Suggested reconstitution Reconstitute the 10 mg vial with 2 mL bacteriostatic water → 5.0 mg/mL (5000 mcg/mL)
Concentration—
Volume / aliquot—
U-100 units—
Aliquots / vial—
Concentration = compound ÷ diluent. Volume per aliquot = target ÷ concentration. U-100 units are a volume readout (1 mL = 100 units). Figures are for research solution preparation only — not instructions for use in humans or animals.
010

What the research flags

Adverse effects and open safety questions noted in published and preclinical sources. This is information, not guidance for use.

Injection-site reactions Reported
Redness, swelling, or irritation at administration sites is the most commonly reported effect in research and user accounts.
Immunogenicity FDA concern
Potential for antibody formation with repeated exposure was cited among FDA Category 2 considerations. No long-term human data exists.
No completed human trials Key gap
The large majority of evidence comes from rodent studies. Human efficacy and long-term safety remain uncharacterized.
Interaction unknowns unknown
Effects alongside medications or in people with existing conditions have not been studied - part of why the compound is restricted to research contexts.
011

Signs of a quality compound

Lyophilised cake or powder
A fine, fluffy white cake — not oily, clumped or discoloured.
Clear reconstitution
Dissolves to a clear, colourless solution with no visible particles or cloudiness.
Batch-specific COA
Independent HPLC purity and mass-spec identity for the exact lot — not a recycled generic PDF.
Intact seal & vacuum
Sealed flip-top vial under vacuum; correct fill; legible batch and storage marking.
Walk away if…
No COA, oily residue, off-colour, partial vacuum, or purity claims with no independent test behind them.
Suspiciously cheap
Pricing far below the market for a well-tested compound usually means skipped testing or underfilled vials.
Regulatory & status
From gray market to formal review.

BPC-157 spent years on the FDA's 503A Category 2 bulks list, which restricted compounding-pharmacy preparation. In 2026 it was moved back toward Category 1 under revised HHS guidance, easing that specific restriction — but it remains an unapproved investigational compound, legitimately sold only as a research material.

Status
Investigational research compound
2026 shift
Moved off FDA Category 2 bulks restriction
Approval
Not FDA-approved for human use
Anti-doping
Prohibited in sport (WADA-listed)
Research handling
Important notices
  • For research purposes only
  • Not for human consumption
  • Not FDA approved
  • Consult a qualified professional
Important

For research use only. Not for human consumption. Apex Academy is an educational reference describing findings reported in published and preclinical literature. Nothing here is medical advice, a protocol, or a recommendation to administer any compound to humans or animals. Many compounds described are investigational and are not approved by the FDA or other regulators for the prevention, treatment, or cure of any condition. Their long-term safety and pharmacokinetics remain incompletely characterized. Dose ranges, where shown, describe quantities used in cited research models - not instructions for use. Consult a qualified, licensed professional before making any health decision.